New warning on Avandia as researchers discover it weakens bones
There’s more bad news for GlaxoSmithKline (GSK) and its antidiabetes drug Avandia. The drug already comes with a strong warning that it cause a heart attack, and now researchers have also found it increases the risk of fracture in postmenopausal women.
Avandia (rosiglitazone) and Actos (pioglitazone) may also have the same effect on men who take either drug, too, say researchers from the University of Michigan in Ann Arbor.
They made their discovery when they analysed 786 cases of fractures and matched them against 2,657 diabetes patients who hadn’t suffered a fracture. The drugs seemed to be the one difference between the two groups, and the rate of fractures increased with the dosage.
(Source: Journal of Clinical Endocrinology & Metabolism, July 14, 2010: doi: 10.1210/jc.2009-2638).